In a separate study (Branford et al, 2002), only one out of 10 CML patients with primary resistance to imatinib therapy had a BCR-ABL mutation, suggesting that a different mechanism is responsible in this setting. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.